INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 142 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2019. The put-call ratio across all filers is 2.57 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $600,000 | +212.5% | 11,467 | -8.0% | 0.00% | +100.0% |
Q1 2020 | $192,000 | -75.6% | 12,467 | -45.7% | 0.00% | -50.0% |
Q4 2019 | $788,000 | -24.0% | 22,967 | -83.4% | 0.00% | -33.3% |
Q3 2019 | $1,037,000 | -51.6% | 138,767 | -15.9% | 0.00% | -40.0% |
Q2 2019 | $2,141,000 | +39.7% | 164,967 | +31.1% | 0.01% | +25.0% |
Q1 2019 | $1,533,000 | +376.1% | 125,867 | +345.3% | 0.00% | +300.0% |
Q4 2018 | $322,000 | – | 28,267 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sarissa Capital Management LP | 675,000 | $26,203,000 | 7.44% |
EcoR1 Capital, LLC | 244,950 | $9,509,000 | 3.75% |
Redmile Group, LLC | 971,565 | $37,716,000 | 3.60% |
Ghost Tree Capital, LLC | 120,000 | $4,658,000 | 1.34% |
SENZAR ASSET MANAGEMENT, LLC | 144,624 | $5,614,304,000 | 1.22% |
GREAT POINT PARTNERS LLC | 100,000 | $3,882,000 | 1.11% |
BB BIOTECH AG | 700,000 | $27,174,000 | 1.07% |
Rhenman & Partners Asset Management AB | 115,000 | $4,464,000 | 0.79% |
Lisanti Capital Growth, LLC | 12,260 | $476,000 | 0.72% |
Rock Springs Capital Management LP | 190,000 | $7,376,000 | 0.55% |